Emerging infections research to improve global health
The Duke Human Vaccine Institute (DHVI) continues to lead with cutting edge vaccine research against infectious diseases that impact global health. The investigators at the DHVI conduct basic and translational research to develop novel vaccines, therapeutics and diagnostics for diseases such as HIV-1, tuberculosis, influenza, syphilis, gonorrhea, cytomegalovirus, rotavirus, parainfluenza, zika flavivirus, plague and now SARS-CoV-2. Several DHVI investigator led basic science discoveries are currently being produced in Good Manufacturing Practice (CGMP) facilities for early phase vaccine trials.
